Cargando…

Molecular docking based screening of Listeriolysin-O for improved inhibitors

Listeriolysine-O (LLO) is a 50KDa protein responsible for Listeria monocytogenes pathogenicity. The structure of LLO (PDB ID: 4CDB) with domains D1 to D4 is known. Therefore, it is of interest to identify conserved regions among LLO variants for destabilizing oligomerization (50 mer complex) of its...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghafari, Sara, Komeilian, Matin, Hashemi, Mohaddese sadat, Oushani, Sareh, Rigi, Garshasb, Rashidieh, Behnam, Yarahmadi, Kamran, Khoddam, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498783/
https://www.ncbi.nlm.nih.gov/pubmed/28690383
http://dx.doi.org/10.6026/97320630013160
_version_ 1783248360464973824
author Ghafari, Sara
Komeilian, Matin
Hashemi, Mohaddese sadat
Oushani, Sareh
Rigi, Garshasb
Rashidieh, Behnam
Yarahmadi, Kamran
Khoddam, Fatemeh
author_facet Ghafari, Sara
Komeilian, Matin
Hashemi, Mohaddese sadat
Oushani, Sareh
Rigi, Garshasb
Rashidieh, Behnam
Yarahmadi, Kamran
Khoddam, Fatemeh
author_sort Ghafari, Sara
collection PubMed
description Listeriolysine-O (LLO) is a 50KDa protein responsible for Listeria monocytogenes pathogenicity. The structure of LLO (PDB ID: 4CDB) with domains D1 to D4 is known. Therefore, it is of interest to identify conserved regions among LLO variants for destabilizing oligomerization (50 mer complex) of its monomers using appropriate inhibitors. Therefore, it is of interest to identify suitable inhibitors for inhibiting LLO. Previous reports suggest the use of flavanoids like compounds for inhibiting LLO. Our interest is to identify improved compounds to destabilize LLO oligomerization. We used a library (Zinc database) containing 200,000 drug-like compounds against LLO using molecular docking based screening. This resulted in five hits that were further analyzed for pharmacological properties. The hit #1 (2-methyloctadecane- 1, 3, 4-triol) was further refined using appropriate modifications for creating a suitable pharmacophore model LLO inhibition. The modified compound (1-(4-Cyclopent-3-enyl-6, 7-dihydroxy-8-hydroxymethyl-nona-2, 8-dienylideneamino)-penta-1,4-dien-3-one) shows fitting binding properties with LLO with no undesirable pharmacological properties such as toxicity.
format Online
Article
Text
id pubmed-5498783
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Biomedical Informatics
record_format MEDLINE/PubMed
spelling pubmed-54987832017-07-07 Molecular docking based screening of Listeriolysin-O for improved inhibitors Ghafari, Sara Komeilian, Matin Hashemi, Mohaddese sadat Oushani, Sareh Rigi, Garshasb Rashidieh, Behnam Yarahmadi, Kamran Khoddam, Fatemeh Bioinformation Hypothesis Listeriolysine-O (LLO) is a 50KDa protein responsible for Listeria monocytogenes pathogenicity. The structure of LLO (PDB ID: 4CDB) with domains D1 to D4 is known. Therefore, it is of interest to identify conserved regions among LLO variants for destabilizing oligomerization (50 mer complex) of its monomers using appropriate inhibitors. Therefore, it is of interest to identify suitable inhibitors for inhibiting LLO. Previous reports suggest the use of flavanoids like compounds for inhibiting LLO. Our interest is to identify improved compounds to destabilize LLO oligomerization. We used a library (Zinc database) containing 200,000 drug-like compounds against LLO using molecular docking based screening. This resulted in five hits that were further analyzed for pharmacological properties. The hit #1 (2-methyloctadecane- 1, 3, 4-triol) was further refined using appropriate modifications for creating a suitable pharmacophore model LLO inhibition. The modified compound (1-(4-Cyclopent-3-enyl-6, 7-dihydroxy-8-hydroxymethyl-nona-2, 8-dienylideneamino)-penta-1,4-dien-3-one) shows fitting binding properties with LLO with no undesirable pharmacological properties such as toxicity. Biomedical Informatics 2017-05-31 /pmc/articles/PMC5498783/ /pubmed/28690383 http://dx.doi.org/10.6026/97320630013160 Text en © 2017 Biomedical Informatics http://creativecommons.org/licenses/by/3.0/ This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
spellingShingle Hypothesis
Ghafari, Sara
Komeilian, Matin
Hashemi, Mohaddese sadat
Oushani, Sareh
Rigi, Garshasb
Rashidieh, Behnam
Yarahmadi, Kamran
Khoddam, Fatemeh
Molecular docking based screening of Listeriolysin-O for improved inhibitors
title Molecular docking based screening of Listeriolysin-O for improved inhibitors
title_full Molecular docking based screening of Listeriolysin-O for improved inhibitors
title_fullStr Molecular docking based screening of Listeriolysin-O for improved inhibitors
title_full_unstemmed Molecular docking based screening of Listeriolysin-O for improved inhibitors
title_short Molecular docking based screening of Listeriolysin-O for improved inhibitors
title_sort molecular docking based screening of listeriolysin-o for improved inhibitors
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498783/
https://www.ncbi.nlm.nih.gov/pubmed/28690383
http://dx.doi.org/10.6026/97320630013160
work_keys_str_mv AT ghafarisara moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT komeilianmatin moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT hashemimohaddesesadat moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT oushanisareh moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT rigigarshasb moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT rashidiehbehnam moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT yarahmadikamran moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors
AT khoddamfatemeh moleculardockingbasedscreeningoflisteriolysinoforimprovedinhibitors